Investigational Site Number : 0320009

Buenos Aires 1650

2 studies enrolling now · 10 studies all time

What they study most

Asthma, Celiac Disease, Chronic Obstructive Pulmonary Disease, Coeliac Disease, Dermatitis Atopic, Multiple Sclerosis, Type 2 Diabetes Mellitus

Studies at this site

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Recruiting now
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis — Running, not enrolling
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — Running, not enrolling
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials — Enrolling by invitation
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study — Running, not enrolling
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD — Running, not enrolling
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Running, not enrolling
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) — Completed
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease — Running, not enrolling
Effect of Efpeglenatide on Cardiovascular Outcomes — Stopped early